<DOC>
	<DOCNO>NCT00367536</DOCNO>
	<brief_summary>This study involve experimental drug bazedoxifene acetate/conjugated estrogen ( also call BZA/CE ) . This drug approve Food Drug Administration ( FDA ) . About 24 subject take part study . Each subject 's participation study last 10 week . During study , subject receive 3 different type BZA/CE tablet plus oral solution contain BZA . The purpose study learn tablet dosage form dissolve absorb body compare BZA oral solution . In addition , information also learn safety tolerability dosage form give healthy postmenopausal woman .</brief_summary>
	<brief_title>Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution</brief_title>
	<detailed_description />
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Generally healthy , nonsmoking ( smoker le 10 cigarettes/day ) Postmenopausal woman age 35 70 year At least 12 month spontaneous amenorrhea , OR 6 month spontaneous amenorrhea folliclestimulating hormone ( FSH ) level least 38 mIU/mL Women 55 year old must least 12 month amenorrhea Body mass index range 18.0 35.0 , minimum body weight 50 kg A history active presence clinically important medical disease . History alcoholism drug abuse within 1 year study start . Use estrogen , androgen , progestincontaining medication nonoral route administration within 6 month study day 1 must approve Wyeth Research</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Health</keyword>
</DOC>